866-997-4948(US-Canada Toll Free)

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016

Published By :

Global Markets Direct

Published Date : Jun 2016

Category :

Cancer

No. of Pages : 1200 Pages

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016

Summary

Global Markets Directs, Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016, provides an overview of the Kidney Cancer (Renal Cell Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer)
- The report reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Kidney Cancer (Renal Cell Cancer) therapeutics and enlists all their major and minor projects
- The report assesses Kidney Cancer (Renal Cell Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer)


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Kidney Cancer (Renal Cell Cancer)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 9
Kidney Cancer (Renal Cell Cancer) Overview 10
Therapeutics Development 11
Kidney Cancer (Renal Cell Cancer) - Therapeutics under Development by Companies 13
Kidney Cancer (Renal Cell Cancer) - Therapeutics under Investigation by Universities/Institutes 24
Kidney Cancer (Renal Cell Cancer) - Pipeline Products Glance 26
Kidney Cancer (Renal Cell Cancer) - Products under Development by Companies 30
Kidney Cancer (Renal Cell Cancer) - Products under Investigation by Universities/Institutes 48
Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development 50
Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment 196
Drug Profiles 232
Kidney Cancer (Renal Cell Cancer) - Recent Pipeline Updates 745
Kidney Cancer (Renal Cell Cancer) - Dormant Projects 1138
Kidney Cancer (Renal Cell Cancer) - Dormant Projects 1138
Kidney Cancer (Renal Cell Cancer) - Discontinued Products 1160
Kidney Cancer (Renal Cell Cancer) - Product Development Milestones 1165
Appendix 1172

List of Tables
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2016 38
Number of Products under Development for Kidney Cancer (Renal Cell Cancer) - Comparative Analysis, H1 2016 39
Number of Products under Development by Companies, H1 2016 40
Number of Products under Development by Companies, H1 2016 (Contd..1) 41
Number of Products under Development by Companies, H1 2016 (Contd..2) 42
Number of Products under Development by Companies, H1 2016 (Contd..3) 43
Number of Products under Development by Companies, H1 2016 (Contd..4) 44
Number of Products under Development by Companies, H1 2016 (Contd..5) 45
Number of Products under Development by Companies, H1 2016 (Contd..6) 46
Number of Products under Development by Companies, H1 2016 (Contd..7) 47
Number of Products under Development by Companies, H1 2016 (Contd..8) 48
Number of Products under Development by Companies, H1 2016 (Contd..9) 49
Number of Products under Development by Companies, H1 2016 (Contd..10) 50
Number of Products under Investigation by Universities/Institutes, H1 2016 52
Comparative Analysis by Late Stage Development, H1 2016 53
Comparative Analysis by Clinical Stage Development, H1 2016 54
Comparative Analysis by Early Stage Development, H1 2016 55
Comparative Analysis by Unknown Stage Development, H1 2016 56
Products under Development by Companies, H1 2016 57
Products under Development by Companies, H1 2016 (Contd..1) 58
Products under Development by Companies, H1 2016 (Contd..2) 59
Products under Development by Companies, H1 2016 (Contd..3) 60
Products under Development by Companies, H1 2016 (Contd..4) 61
Products under Development by Companies, H1 2016 (Contd..5) 62
Products under Development by Companies, H1 2016 (Contd..6) 63
Products under Development by Companies, H1 2016 (Contd..7) 64
Products under Development by Companies, H1 2016 (Contd..8) 65
Products under Development by Companies, H1 2016 (Contd..9) 66
Products under Development by Companies, H1 2016 (Contd..10) 67
Products under Development by Companies, H1 2016 (Contd..11) 68
Products under Development by Companies, H1 2016 (Contd..12) 69
Products under Development by Companies, H1 2016 (Contd..13) 70
Products under Development by Companies, H1 2016 (Contd..14) 71
Products under Development by Companies, H1 2016 (Contd..15) 72
Products under Development by Companies, H1 2016 (Contd..16) 73
Products under Development by Companies, H1 2016 (Contd..17) 74
Products under Investigation by Universities/Institutes, H1 2016 75
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 76
Kidney Cancer (Renal Cell Cancer) - Pipeline by 4SC AG, H1 2016 77
Kidney Cancer (Renal Cell Cancer) - Pipeline by AbbVie Inc., H1 2016 78
Kidney Cancer (Renal Cell Cancer) - Pipeline by Acceleron Pharma, Inc., H1 2016 79
Kidney Cancer (Renal Cell Cancer) - Pipeline by Advanced Cancer Therapeutics, H1 2016 80
Kidney Cancer (Renal Cell Cancer) - Pipeline by Advaxis, Inc., H1 2016 81
Kidney Cancer (Renal Cell Cancer) - Pipeline by Advenchen Laboratories, LLC, H1 2016 82
Kidney Cancer (Renal Cell Cancer) - Pipeline by Alethia Biotherapeutics Inc., H1 2016 83
Kidney Cancer (Renal Cell Cancer) - Pipeline by Altor BioScience Corporation, H1 2016 84
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ambrx, Inc., H1 2016 85
Kidney Cancer (Renal Cell Cancer) - Pipeline by Amgen Inc., H1 2016 86
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 87
Kidney Cancer (Renal Cell Cancer) - Pipeline by Apcure SAS, H1 2016 88
Kidney Cancer (Renal Cell Cancer) - Pipeline by APEIRON Biologics AG, H1 2016 89
Kidney Cancer (Renal Cell Cancer) - Pipeline by arGEN-X BV, H1 2016 90
Kidney Cancer (Renal Cell Cancer) - Pipeline by Argos Therapeutics, Inc., H1 2016 91
Kidney Cancer (Renal Cell Cancer) - Pipeline by ArQule, Inc., H1 2016 92
Kidney Cancer (Renal Cell Cancer) - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016 93
Kidney Cancer (Renal Cell Cancer) - Pipeline by Astellas Pharma Inc., H1 2016 94
Kidney Cancer (Renal Cell Cancer) - Pipeline by AstraZeneca Plc, H1 2016 95
Kidney Cancer (Renal Cell Cancer) - Pipeline by ATLAB Pharma SAS, H1 2016 96
Kidney Cancer (Renal Cell Cancer) - Pipeline by Aurigene Discovery Technologies Limited, H1 2016 97
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bayer AG, H1 2016 98
Kidney Cancer (Renal Cell Cancer) - Pipeline by Berg LLC, H1 2016 99
Kidney Cancer (Renal Cell Cancer) - Pipeline by BIND Therapeutics, Inc., H1 2016 100
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bio-Cancer Treatment International Limited, H1 2016 101
Kidney Cancer (Renal Cell Cancer) - Pipeline by BIOCAD, H1 2016 102
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionomics Limited, H1 2016 103
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionovis SA, H1 2016 104
Kidney Cancer (Renal Cell Cancer) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 105
Kidney Cancer (Renal Cell Cancer) - Pipeline by Boston Biomedical, Inc., H1 2016 106
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bristol-Myers Squibb Company, H1 2016 107
Kidney Cancer (Renal Cell Cancer) - Pipeline by Caladrius Biosciences, Inc. , H1 2016 108
Kidney Cancer (Renal Cell Cancer) - Pipeline by Calithera Biosciences, Inc., H1 2016 109
Kidney Cancer (Renal Cell Cancer) - Pipeline by CASI Pharmaceuticals Inc., H1 2016 110
Kidney Cancer (Renal Cell Cancer) - Pipeline by Celgene Corporation, H1 2016 111
Kidney Cancer (Renal Cell Cancer) - Pipeline by Cellceutix Corporation, H1 2016 112
Kidney Cancer (Renal Cell Cancer) - Pipeline by Celldex Therapeutics, Inc., H1 2016 113
Kidney Cancer (Renal Cell Cancer) - Pipeline by Celltrion, Inc., H1 2016 114
Kidney Cancer (Renal Cell Cancer) - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 115
Kidney Cancer (Renal Cell Cancer) - Pipeline by Cerulean Pharma, Inc., H1 2016 116
Kidney Cancer (Renal Cell Cancer) - Pipeline by Chipscreen Biosciences Ltd, H1 2016 117
Kidney Cancer (Renal Cell Cancer) - Pipeline by Clonz Biotech Private Limited, H1 2016 118
Kidney Cancer (Renal Cell Cancer) - Pipeline by Coare Biotechnology, Inc., H1 2016 119
Kidney Cancer (Renal Cell Cancer) - Pipeline by Coherus BioSciences, Inc., H1 2016 120
Kidney Cancer (Renal Cell Cancer) - Pipeline by Corcept Therapeutics Incorporated, H1 2016 121
Kidney Cancer (Renal Cell Cancer) - Pipeline by Corvus Pharmaceuticals, Inc., H1 2016 122
Kidney Cancer (Renal Cell Cancer) - Pipeline by Cytune Pharma SAS, H1 2016 123
Kidney Cancer (Renal Cell Cancer) - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 124
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ecrins Therapeutics SAS, H1 2016 125
Kidney Cancer (Renal Cell Cancer) - Pipeline by EirGenix Inc., H1 2016 126
Kidney Cancer (Renal Cell Cancer) - Pipeline by Eisai Co., Ltd., H1 2016 127
Kidney Cancer (Renal Cell Cancer) - Pipeline by Eli Lilly and Company, H1 2016 128
Kidney Cancer (Renal Cell Cancer) - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016 129
Kidney Cancer (Renal Cell Cancer) - Pipeline by Exelixis, Inc., H1 2016 130
Kidney Cancer (Renal Cell Cancer) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 131
Kidney Cancer (Renal Cell Cancer) - Pipeline by Gene Techno Science Co., Ltd., H1 2016 132
Kidney Cancer (Renal Cell Cancer) - Pipeline by Genor BioPharma Co., Ltd., H1 2016 133
Kidney Cancer (Renal Cell Cancer) - Pipeline by GenSpera, Inc., H1 2016 134
Kidney Cancer (Renal Cell Cancer) - Pipeline by GlaxoSmithKline Plc, H1 2016 135
Kidney Cancer (Renal Cell Cancer) - Pipeline by Glycotope GmbH, H1 2016 136
Kidney Cancer (Renal Cell Cancer) - Pipeline by HEC Pharm Co., Ltd., H1 2016 137
Kidney Cancer (Renal Cell Cancer) - Pipeline by Horizon Pharma Plc, H1 2016 138
Kidney Cancer (Renal Cell Cancer) - Pipeline by Hutchison MediPharma Limited, H1 2016 139
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immatics Biotechnologies GmbH, H1 2016 140
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immune Design Corp., H1 2016 141
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunicum AB, H1 2016 142
Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoFrontier, Inc., H1 2016 143
Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoGen, Inc., H1 2016 144
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunomedics, Inc., H1 2016 145
Kidney Cancer (Renal Cell Cancer) - Pipeline by Incuron, LLC, H1 2016 146
Kidney Cancer (Renal Cell Cancer) - Pipeline by Incyte Corporation, H1 2016 147
Kidney Cancer (Renal Cell Cancer) - Pipeline by Innate Immunotherapeutics Ltd, H1 2016 148
Kidney Cancer (Renal Cell Cancer) - Pipeline by Johnson & Johnson, H1 2016 149
Kidney Cancer (Renal Cell Cancer) - Pipeline by KAHR medical Ltd., H1 2016 150
Kidney Cancer (Renal Cell Cancer) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 151
Kidney Cancer (Renal Cell Cancer) - Pipeline by KineMed, Inc., H1 2016 152
Kidney Cancer (Renal Cell Cancer) - Pipeline by Komipharm International Co., Ltd., H1 2016 153
Kidney Cancer (Renal Cell Cancer) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 154
Kidney Cancer (Renal Cell Cancer) - Pipeline by Lead Discovery Center GmbH, H1 2016 155
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mabion SA, H1 2016 156
Kidney Cancer (Renal Cell Cancer) - Pipeline by MacroGenics, Inc., H1 2016 157
Kidney Cancer (Renal Cell Cancer) - Pipeline by MaxiVAX SA, H1 2016 158
Kidney Cancer (Renal Cell Cancer) - Pipeline by MediaPharma s.r.l., H1 2016 159
Kidney Cancer (Renal Cell Cancer) - Pipeline by MedImmune, LLC, H1 2016 160
Kidney Cancer (Renal Cell Cancer) - Pipeline by Medivation, Inc., H1 2016 161
Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck & Co., Inc., H1 2016 162
Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck KGaA, H1 2016 163
Kidney Cancer (Renal Cell Cancer) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 164
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mirati Therapeutics Inc., H1 2016 165
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mirna Therapeutics, Inc., H1 2016 166
Kidney Cancer (Renal Cell Cancer) - Pipeline by Molecular Partners AG, H1 2016 167
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mologen AG, H1 2016 168
Kidney Cancer (Renal Cell Cancer) - Pipeline by Monopar Therapeutics LLC, H1 2016 169
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mycenax Biotech Inc., H1 2016 170
Kidney Cancer (Renal Cell Cancer) - Pipeline by NanoSmart Pharmaceuticals, Inc., H1 2016 171
Kidney Cancer (Renal Cell Cancer) - Pipeline by Nektar Therapeutics, H1 2016 172
Kidney Cancer (Renal Cell Cancer) - Pipeline by NewLink Genetics Corporation, H1 2016 173
Kidney Cancer (Renal Cell Cancer) - Pipeline by Novartis AG, H1 2016 174
Kidney Cancer (Renal Cell Cancer) - Pipeline by NovaTarg Therapeutics, Inc, H1 2016 175
Kidney Cancer (Renal Cell Cancer) - Pipeline by Omeros Corporation, H1 2016 176
Kidney Cancer (Renal Cell Cancer) - Pipeline by OncBioMune Pharmaceuticals Inc., H1 2016 177
Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncobiologics, Inc., H1 2016 178
Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncolys BioPharma Inc., H1 2016 179
Kidney Cancer (Renal Cell Cancer) - Pipeline by OncoMax, H1 2016 180
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 181
Kidney Cancer (Renal Cell Cancer) - Pipeline by Panacea Biotec Limited, H1 2016 182
Kidney Cancer (Renal Cell Cancer) - Pipeline by Peloton Therapeutics, Inc., H1 2016 183
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pfizer Inc., H1 2016 184
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharmicell Co., Ltd., H1 2016 185
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pivotal BioSciences, Inc., H1 2016 186
Kidney Cancer (Renal Cell Cancer) - Pipeline by Plexxikon Inc., H1 2016 187
Kidney Cancer (Renal Cell Cancer) - Pipeline by Prima BioMed Ltd., H1 2016 188
Kidney Cancer (Renal Cell Cancer) - Pipeline by PsiOxus Therapeutics Limited, H1 2016 189
Kidney Cancer (Renal Cell Cancer) - Pipeline by Qu Biologics Inc., H1 2016 190
Kidney Cancer (Renal Cell Cancer) - Pipeline by Recombio S.L, H1 2016 191
Kidney Cancer (Renal Cell Cancer) - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016 192
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sanofi, H1 2016 193
Kidney Cancer (Renal Cell Cancer) - Pipeline by Seattle Genetics, Inc., H1 2016 194
Kidney Cancer (Renal Cell Cancer) - Pipeline by Selvita S.A., H1 2016 195
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sevion Therapeutics, Inc., H1 2016 196
Kidney Cancer (Renal Cell Cancer) - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016 197
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sillajen Biotherapeutics, H1 2016 198
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sorrento Therapeutics, Inc., H1 2016 199
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 200
Kidney Cancer (Renal Cell Cancer) - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016 201
Kidney Cancer (Renal Cell Cancer) - Pipeline by Synthon Holdings BV, H1 2016 202
Kidney Cancer (Renal Cell Cancer) - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 203
Kidney Cancer (Renal Cell Cancer) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 204
Kidney Cancer (Renal Cell Cancer) - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016 205
Kidney Cancer (Renal Cell Cancer) - Pipeline by Taris Biomedical LLC, H1 2016 206
Kidney Cancer (Renal Cell Cancer) - Pipeline by TC BioPharm Limited, H1 2016 207
Kidney Cancer (Renal Cell Cancer) - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 208
Kidney Cancer (Renal Cell Cancer) - Pipeline by Theravectys SA, H1 2016 209
Kidney Cancer (Renal Cell Cancer) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 210
Kidney Cancer (Renal Cell Cancer) - Pipeline by Tocagen Inc., H1 2016 211
Kidney Cancer (Renal Cell Cancer) - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016 212
Kidney Cancer (Renal Cell Cancer) - Pipeline by TVAX Biomedical, Inc., H1 2016 213
Kidney Cancer (Renal Cell Cancer) - Pipeline by Tyrogenex, Inc., H1 2016 214
Kidney Cancer (Renal Cell Cancer) - Pipeline by United BioPharma, Inc., H1 2016 215
Kidney Cancer (Renal Cell Cancer) - Pipeline by UroGen Pharmaceuticals, Ltd., H1 2016 216
Kidney Cancer (Renal Cell Cancer) - Pipeline by Vascular Biogenics Ltd., H1 2016 217
Kidney Cancer (Renal Cell Cancer) - Pipeline by Vault Pharma Inc., H1 2016 218
Kidney Cancer (Renal Cell Cancer) - Pipeline by Vaxeal Holding SA, H1 2016 219
Kidney Cancer (Renal Cell Cancer) - Pipeline by ViiV Healthcare Limited, H1 2016 220
Kidney Cancer (Renal Cell Cancer) - Pipeline by Vyriad, H1 2016 221
Kidney Cancer (Renal Cell Cancer) - Pipeline by X4 Pharmaceuticals, Inc., H1 2016 222
Assessment by Monotherapy Products, H1 2016 223
Assessment by Combination Products, H1 2016 224
Number of Products by Stage and Target, H1 2016 226
Number of Products by Stage and Mechanism of Action, H1 2016 245
Number of Products by Stage and Route of Administration, H1 2016 256
Number of Products by Stage and Molecule Type, H1 2016 258
Kidney Cancer (Renal Cell Cancer) Therapeutics - Recent Pipeline Updates, H1 2016 772
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2016 1165
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..1), H1 2016 1166
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..2), H1 2016 1167
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..3), H1 2016 1168
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..4), H1 2016 1169
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..5), H1 2016 1170
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..6), H1 2016 1171
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..7), H1 2016 1172
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..8), H1 2016 1173
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..9), H1 2016 1174
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..10), H1 2016 1175
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..11), H1 2016 1176
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..12), H1 2016 1177
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..13), H1 2016 1178
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..14), H1 2016 1179
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..15), H1 2016 1180
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..16), H1 2016 1181
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..17), H1 2016 1182
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..18), H1 2016 1183
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..19), H1 2016 1184
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..20), H1 2016 1185
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..21), H1 2016 1186
Kidney Cancer (Renal Cell Cancer) - Discontinued Products, H1 2016 1187
Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..1), H1 2016 1188
Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..2), H1 2016 1189
Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..3), H1 2016 1190
Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..4), H1 2016 1191

List of Figures
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2016 38
Number of Products under Development for Kidney Cancer (Renal Cell Cancer) - Comparative Analysis, H1 2016 39
Number of Products under Development by Companies, H1 2016 40
Number of Products under Investigation by Universities/Institutes, H1 2016 51
Comparative Analysis by Late Stage Development, H1 2016 53
Comparative Analysis by Clinical Stage Development, H1 2016 54
Comparative Analysis by Early Stage Products, H1 2016 55
Assessment by Monotherapy Products, H1 2016 223
Assessment by Combination Products, H1 2016 224
Number of Products by Top 10 Targets, H1 2016 225
Number of Products by Stage and Top 10 Targets, H1 2016 225
Number of Products by Top 10 Mechanism of Actions, H1 2016 244
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 244
Number of Products by Top 10 Routes of Administration, H1 2016 255
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 255
Number of Products by Top 10 Molecule Types, H1 2016 257
Number of Products by Stage and Top 10 Molecule Types, H1 2016 257

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *